logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. The need for wider utilization of thrombolytic therapy. Discussion.

    Article - En anglais

    Antithrombotic and thrombolytic therapies confer clear net benefits in the treatment of acute myocardial infarction (AMI).

    Antithrombotic therapy with aspirin yields conclusive reductions in vascular mortality as well as reinfarction and stroke and should be administered to all patients with suspected AMI.

    There is presently no clear evidence of net benefits from adding either delayed subcutaneous or immediate intravenous heparin to an antithrombotic regimen of aspirin.

    Direct thrombin inhibitors have theoretical advantages over heparin as antithrombotic agents, but further data are needed from large-scale randomized trials to determine whether these agents confer net benefits when given in conjunction with aspirin.

    Thrombolytic therapy yields clear reductions in mortality and should be considered for all patients with suspected AMI presenting within 12 h of symptom onset.

    The differences in the efficacy, safety, or ease of administration of the various thrombolytic agents are small compared with the substantial benefits that would result from the wider use and earlier administration of any of the available agents.

    More widespread use of antithrombotic and thrombolytic therapies for AMI as well as earlier administration of thrombolytics could prevent tens of thousands of premature deaths annually in the United States alone, and hundreds of thousands worldwide.

    Mots-clés Pascal : Infarctus, Myocarde, Aigu, Fibrinolytique, Inhibiteur thromboagrégation, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Homme, Appareil circulatoire pathologie, Cardiopathie coronaire, Myocarde pathologie

    Mots-clés Pascal anglais : Infarct, Myocardium, Acute, Fibrinolytic, Antiplatelet agent, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Human, Cardiovascular disease, Coronary heart disease, Myocardial disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0161231

    Code Inist : 002B02G. Création : 21/07/1998.